Aromatase inhibitors are used in selected patient subgroups such as women with larger, hormone-receptor-rich breast cancer after menopause, usually because of tumor biology or patient characteristics that do not require systemic chemotherapy35,36,51. This evidence concerns the gene CYP19A1 and breast carcinoma.